Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Session 405: Joint American College of Cardiology/New England Journal of Medicine Late-breaking Clinical Trials II
Transcatheter Aortic Valve Replacement in Patients with Severe Bicuspid Aortic Valve Stenosis at Low Predicted Risk of Mortality
March 29 | 8:15 a.m. CT
Presented by: Basel Ramlawi, M.D.
Session 406: Late-breaking Clinical Trials III
Catheter-based Renal Denervation in the Absence of Antihypertensive Medications: Primary Results from the SPYRAL HTN-OFF MED Pivotal Trial
March 29 | 11:30 a.m. CT
Presented by: Prof. Michael Böhm
Optimizing Outcomes in Transcatheter Aortic Valve Implantation
Transcatheter Aortic Valve Implant Depth Measurements Differ by Aortography versus Computed Tomography
March 28
Presented by: Amit N. Vora, M.D.
Optimizing Outcomes in Transcatheter Aortic Valve Implantation
5-year Health Status Outcomes after Self-expanding Transcatheter or Surgical Aortic Valve Replacement in High-risk Patients with Severe Aortic Stenosis
March 28
Presented by: Suzanne Arnold, M.D.
Arrhythmias and Clinical EP: Devices 3
Use of Clinic Management Software to Evaluate the Effectiveness of Care Pathways for Cardiac Device Patients with Atrial Fibrillation
March 28
Presented by: Melissa Allen, CCT, LMR, CCDS
Highlighted Original Research: Interventional Cardiology and the Year in Review
One-month Dual Antiplatelet Therapy in High Bleeding Risk Patients: Primary Results from the Onyx ONE Clear Study
March 28
Presented by: Ajay Kirtane M.D.
Highlighted Original Research: Interventional Cardiology and the Year in Review
Leaflet Thickening or Immobility in Transcatheter or Surgical Aortic Valves: Results from the EVOLUT Low Risk LTI Substudy
March 28
Presented by: Jeffrey Popma, M.D.
Advancing 1-month DAPT evidence in highly complex high bleeding risk patients, including subjects from the U.S. and Japan.*
Learn About The Study*Resolute Onyx™ DES is not currently indicated for high bleeding risk patients on 1-month DAPT in the United States.
Learn more about EvolutTM TAVR hemodynamics — and why EOAs, gradients, and patient-prosthesis mismatch all matter in TAVR.
Review the DataCAUTION: Investigational device. Limited by federal (U.S.) law to investigational use.